MMP9 and coronary artery disorder: Moreover, a recent study reported the efficiency of combined therapy with rosuvastatin and ezetimibe to treat plaque instability and cardiovascular inflammation in CAD patients, by a significant decrease in MMP-9 plasma concentration [63].